




The relative strengths and weaknesses of Karyopharm Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Karyopharm Therapeutics Inc compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 2.1% points. The greatest weakness of Karyopharm Therapeutics Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 126% points.

The company's Economic Capital Ratio, given in the ranking table, is 140%, being 116% points below the market average of 256%.

Input Variable	Value in 1000 USD
Assets, Current	276,531
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	60,203
Liabilities, Non-Current	11,285
Other Assets	34,300
Other Compr. Net Income	555
Other Expenses	3,014
Other Liabilities	191,016
Other Net Income	-24,114
Other Revenues	108,085
Property and Equipment	2,219
Research and Development	150,813
Selling, General and Administrative Expense	126,417

Output Variable	Value in 1000 USD
Assets	313,050
Liabilities	262,504
Expenses	280,244
Revenues	108,085
Stockholders Equity	50,546
Net Income	-196,273
Comprehensive Net Income	-195,996
BaseVar	494,276
ECR before Limited Liability	-30%
Economic Capital Ratio	140%